Welcome to our dedicated page for Arcus Develop news (Ticker: ARCUF), a resource for investors and traders seeking the latest updates and insights on Arcus Develop stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcus Develop's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcus Develop's position in the market.
Arcus Development Group (OTC: ARCUF) closed a $2.0 million non‑brokered unit offering at $0.25 per unit on January 29, 2026. Each unit included one common share and one warrant exercisable at $0.32 until January 29, 2028.
Proceeds will fund general working capital and work at the Touleary project in the White Gold District, Yukon. Securities carry a four‑month hold period expiring May 30, 2026. One director subscribed for 200,000 units ($50,000); the company relied on MI 61‑101 exemptions. Securities are not registered in the U.S.
